Bank of New York Mellon
PMCB icon

Bank of New York Mellon’s PharmaCyte Biotech PMCB Stock Holding History

Bank of New York Mellon’s Portfolio PMCB Stock Details PMCB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-16,598
Closed -$35.9K – 4276
2023
Q4 		$35.9K Buy
16,598
+5
+0% +$11 ﹤0.01% 4187
2023
Q3 		$34.8K Hold
16,593
– – ﹤0.01% 4199
2023
Q2 		$47.5K Buy
+16,593
New +$49.8K ﹤0.01% 4187

Other funds holding PMCB

KPF
K2 Principal Fund Toronto, Ontario, Canada $1.36B AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EPM
Equitec Proprietary Markets Chicago, Illinois $559M AUM 230.29% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bank of New York Mellon's PMCB Position: Q1 2024 in Review

Bank of New York Mellon sold out of PharmaCyte Biotech (PMCB) in Q1 2024, closing a stake of 16,598 shares — an estimated $35.9K sold.

Bank of New York Mellon first reported a position in PMCB in Q2 2023 and held it in 3 quarters. The position peaked at $47.5K in Q2 2023. 29 funds tracked by Wall St. Rank hold PMCB as of Q1 2024.

  • Bank of New York Mellon reported no remaining PharmaCyte Biotech position as of Q1 2024 after selling out during the quarter.
  • Bank of New York Mellon sold 16,598 PharmaCyte Biotech shares in Q1 2024, an estimated $35.9K.
  • Bank of New York Mellon first reported a position in PharmaCyte Biotech in Q2 2023 and held it in 3 quarters.
  • Bank of New York Mellon's PharmaCyte Biotech position peaked at $47.5K in Q2 2023.
  • 29 funds tracked by Wall St. Rank held PharmaCyte Biotech as of Q1 2024.

Based on Bank of New York Mellon's 13F filing for Q1 2024, filed 25 Apr 2024.